Benitec Biopharma Inc. (BNTC) News
Track canonical SquawkNews coverage tagged to BNTC, Benitec Biopharma Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Benitec Biopharma Price Target Raised to $17.00/Share From $16.00 by Wedbush
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 01:48 PM UTC
L
Benitec Biopharma Inc. FY 2026: Revenue $0 EPS $(0.98) — 10-K Summary
Benitec Biopharma Inc. reported a net loss of $45.5M for fiscal 2026, compared with a $37.9M loss in fiscal 2025, with no product revenue recognized in either year and diluted EPS of $(0.98) for FY 2026 versus $(1.05) in
EARNINGS | Sep 14, 2026, 08:26 PM UTC
L
Benitec Biopharma reports FY2026 net loss $45.5M, cash $180.0M; advances BB-301 clinical program
Benitec Biopharma reported a net loss of $45.5 million for the year ended June 30, 2026, compared with a $37.9 million loss the prior year, and held $180.0 million in cash and cash equivalents at year-end. Total operatin
EARNINGS | Sep 14, 2026, 08:14 PM UTC
L
BNTC: Net loss widened to $45.5M in FY 2026, with $180M cash on hand and no revenue generated
The company reported a net loss of $45.5 million for FY 2026, with no revenue and increased R&D and G&A expenses. Cash reserves of $180 million are expected to fund operations for at least twelve months, but ongoing loss
EARNINGS | Sep 14, 2026, 08:13 PM UTC
L
BNTC: BB-301 clinical progress and robust cash reserves highlight a year of operational and financial momentum
BB-301 clinical development advanced with full enrollment of Cohort 2 and positive interim results, while a strong cash position of $180 million supports ongoing operations. Net loss widened to $45.5 million as R&D and G
EARNINGS | Sep 14, 2026, 08:06 PM UTC
L
Benitec Biopharma FY26 Loss $45.5M >BNTC
Benitec Biopharma FY26 Loss $45.5M >BNTC
EQUITY | Sep 14, 2026, 08:01 PM UTC
L
BNTC - Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
BNTC - Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
EARNINGS | Sep 14, 2026, 08:00 PM UTC
L
BNTC Initiated Outperform W/$16.00 PT at Wedbush
BNTC Initiated Outperform W/$16.00 PT at Wedbush
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC